Aplife Biotech
case study
Biosensors discovery platform
Pre-Seed
Buenos Aires, Argentina

What's the Problem?

The majority of diagnostic tests are currently carried out, after consultation with a clinician, by technical professionals in centralized laboratories using very high-cost equipment. But this is changing, as the health system is moving towards telemedicine and mobile health, in which Lab-on-a-Chip technologies, wearables and point of care (PoC) devices allow carrying out the tests closer to, and even on, the patient. These advances enable health professionals early access to results, making better decisions regarding possible treatments and moving the focus towards prevention. In essence, all these tests depend on the capacity of a molecule (receptor or transducer) to bind specifically to a target of interest (target) such as indicators of pathologies, viruses, or even environmental pollution. Some examples are monoclonal antibodies in a pregnancy test or an enzyme in a glucometer. Electrochemical biosensors are the quintessential devices that can bring diagnosis closer to the patient and provide faster responses in hospitals, at doctors' offices, during an emergency transfer, at home or even in remote rural areas. But finding new receptors is very costly, takes years and is the current restraint to the growth of the biosensor market.

Aplife Biotech
Aplife Biotech
Aplife Biotech
Aplife Biotech

How are they Solving it?

Aplife’s AptiveX technology will for the first time enable biosensor companies access to a receptor discovery platform specifically designed to be used in digital devices unleashing the full potential growth of this market. AptiveX consists of a system for manufacturing combinatorial libraries of millions of molecules bound at predefined locations on CMOS chips that will transform molecular interactions into measurable signals. The system identifies potential receptors individually in one step, does not depend on enzymes allowing molecules with unlimited modifications to be used and each screening run provides the data of many millions of interactions that will feed Machine Learning algorithms for improving the discovery efficiency and design of libraries for specific purposes. With a huge application field, AptiveX will not only be used for the development of biomarker panels, high throughput proteome assays, the early detection of disease and the routine monitoring of risk factors in people but also in other fields such as cosmetics, agriculture, environmental monitoring, and the monitoring of industrial processes.

argenTAG

Next Startup

argenTAG